Zim Laboratories Ltd

- No specific mention of new fundraising through debt or equity in the provided transcript. - Utilization of consideration received on escrow shares was primarily for reducing cash credit and working capital loans, which helps lower borrowing costs going forward (Page 6). - Current CAPEX projects are ongoing but similar in scale to previous years; no indication of new debt/equity raising tied to CAPEX (Page 6). - No explicit plans or commentary related to fresh fundraising activities were discussed during the Q&A or management commentary sections. - The company is focusing on improving operational efficiency, reducing borrowing costs, and utilizing internal resources for ongoing projects. In summary, based on the available information, ZIM Laboratories has not indicated any current or imminent plans for fresh fundraising via debt or equity.

- Current CAPEX is ongoing, primarily focused on two projects similar to previous year's investments. - Newly completed warehouse as part of infrastructure development. - Rs. 181 million added to gross block in Q1, mainly for the new warehouse construction. - No mention of major new CAPEX lined up distinctly for FY24 or FY25 beyond ongoing projects. - Strategic investments include expanding presence in regulated markets like Europe, Australia, and New Zealand through subsidiaries and marketing partners. - Investment in R&D continues strong, with Rs. 53 million spent in Q1 FY24 (~8% of operating income) to support new product innovations and dossier filings. - Focus on diversifying market reach to LATAM, Pharmerging, and other developed markets to improve product quality and returns. - Utilization of funds from escrow shares primarily for reducing cash credit and working capital loans, improving financial health.

- The company expects a mid-teen growth rate in its base business, though a detailed revised guidance will be clearer after Q2 (Page 7). - Growth from Novel In-house Products (NIP) is anticipated to increase significantly in coming quarters, driven by expanding sales in Rest of World (RoW), emerging, and domestic markets (Page 13-14). - Revenues from Europe will start generating by end of next year once EU registrations are completed, bringing higher margins and better ROI (Page 14). - Despite recent setbacks due to currency/dollar shortages and delayed shipments, the company plans to recoup lost sales in Pharma and market NIP products aggressively (Page 15-16). - The Oral Thin Film (OTF) segment is at an early stage but holds long-term potential as acceptance grows globally (Page 11-12). - Expansion into new markets like LATAM, Australia, and New Zealand is underway to diversify revenue sources (Page 8, 16). - R&D investment continues to support sustainable innovation aimed at long-term growth (Page 13).

- Management anticipates mid-teen revenue growth, with detailed revised guidance expected by end of Q2 FY24. (Page 6) - Earnings before interest, taxes, depreciation, and amortization (EBITDA) for Q1 FY24 was Rs. 59 million with EBITDA margin at 8.8%, and Profit After Tax (PAT) at Rs. 2 million (0.3% margin), reflecting temporary challenges. (Page 4) - Return on investment in New Innovative Products (NIPs) has begun, with Rs. 47 million revenue in Q1 FY24 from NIPs, expected to grow significantly in upcoming quarters. (Page 13, Page 4) - Oral Thin Film (OTF) products recently entered European markets; revenue from these is expected to increase as marketing authorizations and filings progress. (Page 14, Page 4) - Despite near-term currency and export headwinds, management remains confident in overcoming challenges and achieving sustainable growth and profitability. (Page 4) - Margin improvement anticipated as company enters regulated markets with higher margin products. (Page 5) - Investment in R&D (~8% of operating income) supports future growth; payback improving as NIP revenue rises. (Page 4, Page 13)

- There were delayed orders in Q1 FY24 due to US dollar shortage in certain RoW markets, especially impacting nutraceutical sales. - The postponed orders mainly arose from currency shortages; the contracts remain active. - A significant portion of these deferred orders has already been received in Q2 FY24. - The company anticipates the dollar shortage issue to stabilize and normalize going forward. - PFI (Pharmaceutical Formulation Ingredients) business orders that were shifted from Q1 to Q2 are expected to compensate part of the lost sales. - No specific quantitative figures were disclosed for the current pending orderbook or overall expected order backlog. - Management indicated that more clarity on orderbook and revenue guidance will be available after Q2 FY24, as the situation stabilizes.